62 related articles for article (PubMed ID: 29519604)
21. The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
Zhang X; Bao B; Yu X; Tong L; Luo Y; Huang Q; Su M; Sheng L; Li J; Zhu H; Yang B; Zhang X; Chen Y; Lu W
Bioorg Med Chem; 2013 Nov; 21(22):6981-95. PubMed ID: 24095018
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
23. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
25. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
28. The application of click chemistry in the synthesis of agents with anticancer activity.
Ma N; Wang Y; Zhao BX; Ye WC; Jiang S
Drug Des Devel Ther; 2015; 9():1585-99. PubMed ID: 25792812
[TBL] [Abstract][Full Text] [Related]
29. Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent.
Patel P; Wahan SK; Vishakha S; Kurmi BD; Gupta GD; Rajak H; Asati V
Curr Cancer Drug Targets; 2022; 23(1):47-70. PubMed ID: 35747969
[TBL] [Abstract][Full Text] [Related]
30. Multi-targeted histone deacetylase inhibitors in cancer therapy.
Ai T; Cui H; Chen L
Curr Med Chem; 2012; 19(4):475-87. PubMed ID: 22204328
[TBL] [Abstract][Full Text] [Related]
31. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.
Li X; Xu W
Drug Discov Ther; 2014 Oct; 8(5):225-8. PubMed ID: 25382558
[TBL] [Abstract][Full Text] [Related]
32. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Liu T; Wan Y; Xiao Y; Xia C; Duan G
J Med Chem; 2020 Sep; 63(17):8977-9002. PubMed ID: 32320239
[TBL] [Abstract][Full Text] [Related]
33. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.
Stiborová M; Eckschlager T; Poljaková J; Hraběta J; Adam V; Kizek R; Frei E
Curr Med Chem; 2012; 19(25):4218-38. PubMed ID: 22680633
[TBL] [Abstract][Full Text] [Related]
34. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
[TBL] [Abstract][Full Text] [Related]
35. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
36. Harnessing pyrimidine as a building block for histone deacetylase inhibitors.
Badran MM; Abbas SH; Fujita M; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Oct; 356(10):e2300208. PubMed ID: 37462396
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]